Overview


Minagene's proprietary solution utilizes whole-genome sequencing directly from sputum and other clinical samples to rapidly detect Mycobacterium tuberculosis complex and identify genetic mutations associated with drug resistance.


Methodology



Specimens undergo phenol-chloroform


Specimens undergo phenol-chloroform extraction followed by Nextera XT library preparation and Illumina sequencing. A curated pathogen database enables identification of Mtb from sequencing reads. Algorithms further characterize resistance-conferring variants across all anti-TB drug targets.


Key Highlights of Minagene’s Tuberculosis Diagnostics Solution


Key Highlights of Minagene’s


-Detects Mtb directly from specimens in hours, not weeks


-Sensitively identifies non-tuberculous mycobacteria


-Assesses mutations for all first and second-line drugs


-Predicts multidrug resistant/extensively drug resistant profiles


-Guides early optimization of personalized treatment regimens


By applying an unbiased meta’omic approach, this solution resolves diagnostic delays impairing TB control. Rapid resistance data supports effective empiric therapy selection while limiting further transmission of resistant strains.


When to Consider Minagene’s Tuberculosis Diagnostics Solution


Physicians should utilize Minagene's sequencing-based TB diagnostic in confirmed or suspected cases where rapid anti-microbial stewardship is paramount to improving patient outcomes and public health.










Overview


Minagene's proprietary SES utilizes metagenomic sequencing and bioinformatics to establish molecular diagnoses in patients presenting with sepsis, bacteremia or other systemic inflammatory responses of unknown etiology.


Methodology



Blood and other sterile site


Blood and other sterile site specimens are subjected to shotgun sequencing on the Illumina platform post-nucleic acid purification. Metagenomic analysis characterizes the circulating pathogenomic and identifies resistance genes by comparison against curated pathogen databases.


Key Highlights of Minagene’s (SES) of Systemic Infections


Key Highlights of Minagene’s (SES)


-Detects viruses, bacteria, fungi, parasites from whole blood


-Identifies causative organisms in culture-negative cases


-Assesses antibiotic resistance without culture-based assumptions


-Streamlines infection control by specifying pathogenic source


-Returns results within 5 days to guide targeted antimicrobials


By applying an unbiased “whole-microbiome” approach, SES addresses diagnostic challenges in sterile site infections. Simultaneous resistance profiling enables optimized, narrow-spectrum empiric therapy selection.


When to Consider


SES is recommended for evaluation of sepsis, infective endocarditis or other life-threatening systemic infections with negative conventional microbiologic workup requiring fast diagnosis.










Overview


Minagene's proprietary gastrointestinal pathogen panel utilizes multiplex PCR and next-generation sequencing to simultaneously detect over 30 bacterial, viral and parasitic organisms associated with acute and chronic diarrhea.


Methodology



Stool specimens


Stool specimens are treated with a lysis buffer and nucleic acid is extracted. Hypervariable regions are amplified using tiled primers barcoded for each pathogen. Sequencing on the Illumina platform at >10,000x coverage allows for identification of variants associated with antimicrobial resistance.


Key Highlights


Key Highlights


-Identifies causative agents missed by conventional assays


-Screens for emerging enteric pathogens like Cyclospora


-Assesses antibiotic resistance of detected bacteria


-Provides results within 5 days to guide targeted therapy


-Offers cost savings compared to sequential single-target testing



With its unparalleled breadth and speed, Minagene’s stool panel streamlines the diagnostic evaluation of gastroenteritis. Genome-resolved pathogen data assists clinical decision-making and public health monitoring of infectious outbreaks.


When to Consider Minagene’s Gastrointestinal Pathogen Test


This comprehensive test is recommended for patients with severe or prolonged diarrhea, particularly in transplant, oncology or malnourished populations where opportunistic infections necessitate rapid diagnosis and isolation.










Overview


Minagene's proprietary SES protocol concurrently isolates and
identifies causative organisms from bilateral ocular swabs, streamlining diagnosis of bacterial conjunctivitis, blepharitis,
keratitis and endophthalmitis. Deep sequencing with
bioinformatic analyses achieve comprehensive pathogen
detection from a single specimen.


Methodology



The Syndrome Evaluation System


The Syndrome Evaluation System (SES) is a patented technology used for rapid multiplex amplification and accurate identification of virulence-associated genes of causative agents or organisms. This advanced platform surpasses conventional diagnostic tests by providing fast and precise results, especially when organisms are challenging to cultivate or locate. Currently available diagnostic technologies for detecting infections are inadequate, often failing to detect early stages of illness and delaying specific therapy in critical cases, which can lead to functional loss or even loss of life.



The SES amplifies genes


The SES amplifies genes, enhancing the sensitivity of the test. The re-naturation of the amplified signature gene to its chemically identified complementary gene sequence on the SES further improves accuracy.



Key Highlights of Minagene's Eye Infections Test


Higher Accuracy


Detects a greater number of cases compared to conventional methods


Reduction in Testing and Investigations


Avoids the need for multiple testing and unnecessary investigations, leading to cost savings.
Reduces the duration of stay in the intensive care unit (ICU) and associated costs.


Comprehensive Pathogen Detection


– Detects DNA of various pathogens, including fungi, viruses, parasites, and bacteria, in a single test.


-Capable of detecting both unimicrobial and polymicrobial infections.


Efficient Rule-in or Rule-out


Helps in confirming or excluding the presence of infections





















Methodology



The Syndrome Evaluation System


The Syndrome Evaluation System (SES) is a patented technology used for rapid multiplex amplification and accurate identification of virulence-associated genes of causative agents or organisms. This advanced platform surpasses conventional diagnostic tests by providing fast and precise results, especially when organisms are challenging to cultivate or locate. Currently, available diagnostic technologies for detecting infections are inadequate, often failing to detect early stages of illness and delaying specific therapy in critical cases, which can lead to functional loss or even loss of life.


The SES amplifies genes, enhancing the sensitivity of the test. The renaturation of the amplified signature gene to its chemically identified complementary gene sequence on the SES further improves accuracy.


Key Highlights of Minagene's CNS Infections Test:


Higher Accuracy


Detects a greater number of cases compared to conventional methods


Reduction in Testing and Investigations


Avoids the need for multiple testing and unnecessary investigations, leading to cost savings


Reduces the duration of stay in the intensive care unit (ICU) and associated costs


Comprehensive Pathogen Detection


Detects DNA of various pathogens, including fungi, viruses, parasites, and bacteria, in a single test.


Capable of detecting both unimicrobial and polymicrobial infections.


Efficient Rule-in or Rule-out


Helps in confirming or excluding the presence of infections


Molecular Basis of Infectious Disease Diagnosis:


Molecular detection


Molecular detection, which involves amplification and hybridization of nucleic acids, has revolutionized the diagnosis of infectious diseases. PCR (Polymerase Chain Reaction) is a commonly used method for nucleic acid detection in clinical laboratories. This approach allows for the direct detection of mutations associated with drug resistance in biological samples without the need for culturing the organism.



molecular basis


The molecular basis of diagnosis offers a new and innovative era in microbial diagnosis, improving the speed and accuracy of identifying infectious diseases. It enables targeted therapy and timely interventions, leading to better patient outcomes.










Your compare list

Compare
REMOVE ALL
COMPARE
0